Drug Trial Radar · NCT07728695
Assessing the Mechanisms and Impact of a Novel Cannabinoid Product for Gynecologic Pain
Last checked: Nov 20, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Sep 2026
Primary completion
Jan 2029
Study completion Jan 2029
Sponsor
- Lead sponsor
- Staci Gruber, Ph.D.Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Center for Complementary and Integrative Health (NCCIH)
- First posted
- Jul 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Despite recent increases in both medical and recreational cannabis use in the United States and globally, little research has been conducted to determine the potential applications for womens health. A variety of medical cannabis and hemp-derived products on the marketplace claim to hold efficacy for many womens health-related conditions, including gynecologic pain. This 7-day study of individuals living with endometriosis, adenomyosis, or chronic pelvic inflammatory disease (PID), will identify specific targets and mechanisms underlying the potential impact of a hemp-derived, full-spectrum, high-CBD product in individuals with gynecologic pain.
Conditions
- Endometriosis
- Adenomyosis
- Chronic Pelvic Inflammatory Disease
Interventions
Custom-formulated, high-CBD study productDrug
2 doses of the high-CBD study product will be used, compared to placebo.
PlaceboDrug
Placebo study product.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Quantification of parent CBD and its primary metabolites, 7-COOH-CBD and 7-OH-CBD, as well as metabolite-to-parent drug exposure ratios (MPR)Time frame: Baseline, 7 days
- Inflammatory markersTime frame: Baseline, 7 days
- Circulating anandamide (AEA)Time frame: Baseline, 7 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
McLean Hospital
Belmont, Massachusetts · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.